

# Key Driver Transforming The Adrenogenital Syndrome Treatment Market 2025: Increasing Adoption Of Personalized Medicines

*The Business Research Company's Key Driver Transforming The Adrenogenital Syndrome Treatment Market 2025: Increasing Adoption Of Personalized Medicines*

LONDON, GREATER LONDON, UNITED KINGDOM, March 24, 2025  
/EINPresswire.com/ -- Updated 2025  
Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



The Business  
Research Company

Adrenogenital Syndrome Treatment Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

## How Has the Adrenogenital Syndrome Treatment Market Performed in Recent Years?

“

It will grow to \$16.19 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%.”

*The Business Research Company*

The adrenogenital syndrome treatment market size has grown strongly in recent years. It is expected to grow from \$12.08 billion in 2024 to \$12.84 billion in 2025, illustrating a compound annual growth rate CAGR of 6.2%. The growth in this historical period can be attributed to increased awareness of rare diseases, an increase in the pediatric population, increasing clinical awareness and education, a rising incidence of hormonal disorders, and increasing access to healthcare services.

## What Is the Outlook for the Adrenogenital Syndrome Treatment Market in the Coming Years?

The adrenogenital syndrome treatment market size is expected to see strong growth in the next few years. It is projected to grow to \$16.19 billion in 2029 at a compound annual growth rate CAGR of 6.0%. The growth in the forecast period can be attributed to increasing genetic research advancements, a growing patient population, rising adoption of targeted therapies, expanding healthcare infrastructure in emerging markets, and increased government funding for rare

disease treatments.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=21086&type=smp>

What Are the Key Drivers for Growth in the Adrenogenital Syndrome Treatment Market Going Forward?

One of the primary growth drivers in the adrenogenital syndrome treatment market is the increasing adoption of personalized medicines. Individualized medicines are treatments tailored to an individual's genetic profile, lifestyle, and health needs for improved efficacy and safety. Particularly for adrenogenital syndrome, these treatments adapt the treatment based on an individual's specific genetic profile and hormone levels, optimizing effectiveness and minimizing side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that FDA approvals for personalized treatments rose to 16 in 2023, including seven for cancer and three for other conditions, up from six in 2022.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/adrenogenital-syndrome-treatment-global-market-report>

Who Leads the Adrenogenital Syndrome Treatment Market Right Now?

Major companies operating in the adrenogenital syndrome treatment market are Pfizer Inc., Thermo Fisher Scientific, Novartis AG, Teva Pharmaceutical Industries Ltd., Lundbeck A/S, Neurocrine Biosciences Inc., Sandoz Group AG, IP Group Plc, BridgeBio Pharma, Bristol Laboratories Ltd, Changi General Hospital Pte Ltd, OMass Therapeutics, Spruce Biosciences Inc., Axplora, Diurnal Ltd., Alder Biopharmaceuticals Inc, Adrenas Therapeutics Inc, Crinetics Pharmaceuticals Inc., EffRx Pharmaceuticals, Millendo Therapeutics Inc.

What Emerging Trends Are Impacting the Adrenogenital Syndrome Market?

A notable emerging trend in the adrenogenital syndrome treatment market is the focus on developing advanced treatment options, such as innovative orphan drugs, by leading companies. These treatments are meant to meet unmet medical needs and improve patient outcomes by offering targeted therapies for rare and complex disorders. A shining example of this trend is the approval of CRENESSITY crinecerfont, an innovative treatment for children and adults with classic Congenital Adrenal Hyperplasia CAH, a type of adrenogenital syndrome, by the U.S. Food and Drug Administration in December 2024.

How Is the Adrenogenital Syndrome Treatment Market Segmented?

The adrenogenital syndrome treatment market covered in this report is segmented based on:

- 1 Drug Type: Mineralocorticoids, Glucocorticoids
- 2 Route of Administration: Oral, Parenteral, Intravenous, Inhaled
- 3 Technology: Genetic Testing Technologies, Hormone Replacement Therapies, Surgical Technologies
- 4 Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
- 5 End-User: Hospitals, Clinics, Home Care Settings

And these key subsegments:

- 1 By Mineralocorticoids: Fludrocortisone, Other Mineralocorticoids
- 2 By Glucocorticoids: Hydrocortisone, Prednisolone, Dexamethasone, Other Glucocorticoids

What About Regional Analysis for the Adrenogenital Syndrome Treatment Market?

In terms of regional coverage, North America emerged as the largest region in the adrenogenital syndrome treatment market in 2024. Other crucial regions covered in the report are Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.

Find More Similar Reports by [The Business Research Company](#):

Congenital Diaphragmatic Hernia Drugs Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report>

Cryogenic Insulation Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/cryogenic-insulation-global-market-report>

Genito-Urinary Drugs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report>

About The Business Research Company

The Business Research Company, with over 15000+ reports from 27 industries covering 60+ geographies, has been a reputable name in providing comprehensive, data-rich research and insights. Holding 1,500,000 datasets in-store, contributions from extensive secondary research, and unique insights from industry leaders, you can benefit from the intelligence you need to stay ahead in your respective market segment.

Contact us at

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_fI0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/796538610>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.